These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8398039)
41. Blood lactate monitoring in critically ill patients: a systematic health technology assessment. Jansen TC; van Bommel J; Bakker J Crit Care Med; 2009 Oct; 37(10):2827-39. PubMed ID: 19707124 [TBL] [Abstract][Full Text] [Related]
42. Positive role of immune nutrition on metabolism in sepsis and multi-organ failure. Georgieff M; Tugtekin IF Kidney Int Suppl; 1998 Feb; 64():S80-3. PubMed ID: 9475496 [TBL] [Abstract][Full Text] [Related]
43. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Seya T; Akazawa T; Uehori J; Matsumoto M; Azuma I; Toyoshima K Anticancer Res; 2003; 23(6a):4369-76. PubMed ID: 14666723 [TBL] [Abstract][Full Text] [Related]
44. Immunotherapy for fungal infections. Segal BH; Kwon-Chung J; Walsh TJ; Klein BS; Battiwalla M; Almyroudis NG; Holland SM; Romani L Clin Infect Dis; 2006 Feb; 42(4):507-15. PubMed ID: 16421795 [TBL] [Abstract][Full Text] [Related]
45. Obesity and sepsis. Vachharajani V; Vital S J Intensive Care Med; 2006; 21(5):287-95. PubMed ID: 16946444 [TBL] [Abstract][Full Text] [Related]
46. Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses. Ely EW; Kleinpell RM; Goyette RE Am J Crit Care; 2003 Mar; 12(2):120-33; quiz 134-5. PubMed ID: 12625170 [TBL] [Abstract][Full Text] [Related]
47. Balance between Hyperinflammation and Immunosuppression in Sepsis. Yadav H; Cartin-Ceba R Semin Respir Crit Care Med; 2016 Feb; 37(1):42-50. PubMed ID: 26820273 [TBL] [Abstract][Full Text] [Related]
48. [Characteristics, indications for and adverse effects of various preparations with immunologic properties]. Niedworok J Wiad Lek; 1988 Aug; 41(15):1039-47. PubMed ID: 3245193 [No Abstract] [Full Text] [Related]
49. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Cohen-Wolkowiez M; Benjamin DK; Capparelli E Curr Opin Pediatr; 2009 Apr; 21(2):177-81. PubMed ID: 19276977 [TBL] [Abstract][Full Text] [Related]
50. Intralesional immunotherapy for the management of warts. Chandrashekar L Indian J Dermatol Venereol Leprol; 2011; 77(3):261-3. PubMed ID: 21508563 [No Abstract] [Full Text] [Related]
52. [Present status and perspectives in immunologic therapy]. Geavlete A Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(3):203-10. PubMed ID: 2891168 [No Abstract] [Full Text] [Related]
53. Using the body's immune system to fight disease: practical immune enhancement. Introduction. Rosen T Postgrad Med; 2002 Dec; 112(6 Suppl Using):3-7. PubMed ID: 19667607 [No Abstract] [Full Text] [Related]
54. [Principles of adjuvant therapy with immunomodulators]. Betzler M Aktuelle Probl Chir Orthop; 1982; 22():24-9. PubMed ID: 6121509 [No Abstract] [Full Text] [Related]
55. 26. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. Nelson RP; Ballow M J Allergy Clin Immunol; 2003 Feb; 111(2 Suppl):S720-43. PubMed ID: 12592317 [TBL] [Abstract][Full Text] [Related]
56. Immunomodulation in the critically ill. Webster NR; Galley HF Br J Anaesth; 2009 Jul; 103(1):70-81. PubMed ID: 19474216 [TBL] [Abstract][Full Text] [Related]
57. Advances in the therapy for sepsis in children. Anderson MR; Blumer JL Pediatr Clin North Am; 1997 Feb; 44(1):179-205. PubMed ID: 9057790 [TBL] [Abstract][Full Text] [Related]